

Megan A Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2586731/publications.pdf>

Version: 2024-02-01

97
papers

4,435
citations

147566

31
h-index

114278

63
g-index

100
all docs

100
docs citations

100
times ranked

4470
citing authors

#	ARTICLE	IF	CITATIONS
1	Reflections from field notes: An oral human papillomavirus infection and oropharyngeal cancer study among Indigenous Australians. <i>Australian Journal of Rural Health</i> , 2022, , .	0.7	0
2	National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study. <i>BMJ, The</i> , 2022, 376, e068582.	3.0	16
3	Oral HPV Infection among Indigenous Australians; Incidence, Persistence, and Clearance at 12-Month Follow-up. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 604-613.	1.1	4
4	Cancer Incidence in Migrants in Australia: Patterns of Three Infection-Related Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1394-1401.	1.1	8
5	Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 268-277.	1.1	24
6	Achieving cervical cancer elimination among Indigenous women. <i>Preventive Medicine</i> , 2021, 144, 106314.	1.6	29
7	Impact of COVID-19-related care disruptions on cervical cancer screening in the United States. <i>Journal of Medical Screening</i> , 2021, 28, 213-216.	1.1	34
8	Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic <sc>HPV</sc> infection and active <sc>HPV</sc> control. <i>International Journal of Cancer</i> , 2021, 149, 297-306.	2.3	5
9	Poor self-rated oral health associated with poorer general health among Indigenous Australians. <i>BMC Public Health</i> , 2021, 21, 424.	1.2	3
10	Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysis. <i>Preventive Medicine</i> , 2021, 144, 106276.	1.6	18
11	Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. <i>PLoS Medicine</i> , 2021, 18, e1003534.	3.9	30
12	Psychometric properties of the EQ-5D-5L for aboriginal Australians: a multi-method study. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 81.	1.0	11
13	Cervical screening during the COVID-19 pandemic: optimising recovery strategies. <i>Lancet Public Health, The</i> , 2021, 6, e522-e527.	4.7	37
14	Active surveillance as a management option for cervical intraepithelial neoplasia 2: An online experimental study. <i>Gynecologic Oncology</i> , 2021, 161, 179-187.	0.6	6
15	Effective HPV vaccination coverage in Australia by number of doses and two-dose spacing: What if one or two doses are sufficient?. <i>Tumour Virus Research</i> , 2021, 11, 200216.	1.5	8
16	Working towards a comprehensive understanding of HPV and cervical cancer among Indigenous women: a qualitative systematic review. <i>BMJ Open</i> , 2021, 11, e050113.	0.8	4
17	Cohort profile: indigenous human papillomavirus and oropharyngeal squamous cell carcinoma study - a prospective longitudinal cohort. <i>BMJ Open</i> , 2021, 11, e046928.	0.8	13
18	A systematic review and meta-analysis of the prevalence of human papillomavirus infection in Indigenous populations – A Global Picture. <i>Journal of Oral Pathology and Medicine</i> , 2021, 50, 843-854.	1.4	7

#	ARTICLE	IF	CITATIONS
19	Population-based utility scores for HPV infection and oropharyngeal squamous cell carcinoma among Indigenous Australians. <i>BMC Public Health</i> , 2021, 21, 1455.	1.2	3
20	Population-based utility scores for HPV infection and cervical squamous cell carcinoma among Australian Indigenous women. <i>PLoS ONE</i> , 2021, 16, e0254575.	1.1	1
21	Eliminating Cervical Cancer: Progress and Challenges for High-income Countries. <i>Clinical Oncology</i> , 2021, 33, 550-559.	0.6	32
22	Facilitating uptake of cervical screening among Indigenous women to achieve equitable and timely elimination of cervical cancer. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 13, 100236.	1.3	4
23	Self-collection for HPV screening: a game changer in the elimination of cervical cancer. <i>Medical Journal of Australia</i> , 2021, 215, 347-348.	0.8	6
24	The impact of HPV vaccination beyond cancer prevention: effect on pregnancy outcomes. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3562-3576.	1.4	5
25	Cost-effectiveness of nonavalent HPV vaccine in Norway considering current empirical data and validation. <i>Preventive Medicine</i> , 2021, 150, 106688.	1.6	1
26	Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis. <i>Preventive Medicine</i> , 2021, 151, 106623.	1.6	34
27	Australian National Cervical Screening Program renewal: Attitudes and experiences of general practitioners, and obstetricians and gynaecologists. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2021, 61, 416-423.	0.4	10
28	School-Level Variation in Coverage of Co-Administered dTpa and HPV Dose 1 in Three Australian States. <i>Vaccines</i> , 2021, 9, 1202.	2.1	4
29	Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 955-963.	3.0	37
30	Diagnosis and Treatment of Chronic Medical Conditions Among Trauma Patients at a Level 1 Trauma Center. <i>American Surgeon</i> , 2020, 86, 1264-1268.	0.4	0
31	High-Risk Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma Among Non-Indigenous and Indigenous Populations: A Systematic Review. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 165, 019459982097504.	1.1	3
32	Historical and projected hysterectomy rates in the USA: Implications for future observed cervical cancer rates and evaluating prevention interventions. <i>Gynecologic Oncology</i> , 2020, 158, 710-718.	0.6	16
33	Prevalence of Oral Human Papillomavirus Infection Among Australian Indigenous Adults. <i>JAMA Network Open</i> , 2020, 3, e204951.	2.8	26
34	Has Human Papillomavirus (HPV) Vaccination Prevented Adverse Pregnancy Outcomes? Population-Level Analysis After 8 Years of a National HPV Vaccination Program in Australia. <i>Journal of Infectious Diseases</i> , 2020, 222, 499-508.	1.9	17
35	The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: A modelling study. <i>PLoS ONE</i> , 2020, 15, e0231388.	1.1	20
36	Projected time to elimination of cervical cancer in the USA: a comparative modelling study. <i>Lancet Public Health</i> , The, 2020, 5, e213-e222.	4.7	59

#	ARTICLE	IF	CITATIONS
37	Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. <i>Lancet Public Health, The</i> , 2020, 5, e223-e234.	4.7	141
38	Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. <i>Lancet, The</i> , 2020, 395, 575-590.	6.3	421
39	Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. <i>Lancet, The</i> , 2020, 395, 591-603.	6.3	321
40	How has COVID-19 impacted cancer screening? Adaptation of services and the future outlook in Australia. <i>Public Health Research and Practice</i> , 2020, 30, .	0.7	41
41	<scp>HPV</scp> swab selfâ€collection and cervical cancer in women who have sex with women. <i>Medical Journal of Australia</i> , 2020, 213, 239.	0.8	10
42	Getting the timing right: Womenâ€™s views on the best time to announce changes to cancer screening policy recommendations. <i>Preventive Medicine Reports</i> , 2020, 20, 101268.	0.8	8
43	Title is missing!. , 2020, 15, e0231388.		0
44	Title is missing!. , 2020, 15, e0231388.		0
45	Title is missing!. , 2020, 15, e0231388.		0
46	Title is missing!. , 2020, 15, e0231388.		0
47	HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 8, 100184.	4.5	41
48	Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. <i>Lancet, The</i> , 2019, 394, 497-509.	6.3	630
49	Cancer elimination thresholds: one size does not fit all â€“ Authors' reply. <i>Lancet Public Health, The</i> , 2019, 4, e87.	4.7	0
50	Towards global elimination of cervical cancer in all groups of women â€“ Authors' reply. <i>Lancet Oncology, The</i> , 2019, 20, e239.	5.1	0
51	The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications. <i>Gynecologic Oncology</i> , 2019, 152, 472-479.	0.6	7
52	Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia. <i>Gynecologic Oncology</i> , 2019, 152, 465-471.	0.6	14
53	Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020â€™99: a modelling study. <i>Lancet Oncology, The</i> , 2019, 20, 394-407.	5.1	279
54	Age-specific HPV prevalence among 116,052 women in Australiaâ€™s renewed cervical screening program: A new tool for monitoring vaccine impact. <i>Vaccine</i> , 2019, 37, 412-416.	1.7	35

#	ARTICLE	IF	CITATIONS
55	A hepatitis B vaccine booster shot at age 10 could be cost-saving in China: But is it too soon to tell?. <i>International Journal of Infectious Diseases</i> , 2019, 78, 128-129.	1.5	1
56	The projected timeframe until cervical cancer elimination in Australia: a modelling study. <i>Lancet Public Health</i> , The, 2019, 4, e19-e27.	4.7	268
57	Lessons from the renewal of the National Cervical Screening Program in Australia. <i>Public Health Research and Practice</i> , 2019, 29, .	0.7	41
58	Inaccurate and fundamentally flawed analysis risks undermining confidence in cervical screening programs. <i>Journal of the American Society of Cytopathology</i> , 2018, 7, 336-338.	0.2	1
59	Anal cancer in high-income countries: Increasing burden of disease. <i>PLoS ONE</i> , 2018, 13, e0205105.	1.1	71
60	Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: Example from New Zealand. <i>Vaccine</i> , 2018, 36, 6314-6324.	1.7	6
61	Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia. <i>PLoS ONE</i> , 2018, 13, e0185332.	1.1	52
62	Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention. <i>JMIR Research Protocols</i> , 2018, 7, e10503.	0.5	17
63	Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. <i>Lancet Public Health</i> , The, 2017, 2, e96-e107.	4.7	124
64	Impact of the National Cervical Screening Programme in New Zealand by age: analysis of cervical cancer trends 1985-2013 in all women and in Māori women. <i>Cancer Causes and Control</i> , 2017, 28, 1393-1404.	0.8	18
65	Cost-effectiveness estimates: the need for complete reporting - Authors' reply. <i>Lancet Public Health</i> , The, 2017, 2, e212.	4.7	2
66	Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 134-141.	4.5	15
67	Vulvar cancer in high-income countries: Increasing burden of disease. <i>International Journal of Cancer</i> , 2017, 141, 2174-2186.	2.3	75
68	How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country. <i>International Journal of Cancer</i> , 2017, 141, 2410-2422.	2.3	25
69	The renewal of the National Cervical Screening Program. <i>Medical Journal of Australia</i> , 2017, 206, 274-274.	0.8	1
70	Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia. <i>PLoS ONE</i> , 2017, 12, e0163509.	1.1	26
71	Impact of HPV sample self-collection for underscreened women in the renewed Cervical Screening Program. <i>Medical Journal of Australia</i> , 2016, 204, 194-194.	0.8	35
72	Impact of the Australian National Cervical Screening Program in women of different ages. <i>Medical Journal of Australia</i> , 2016, 205, 359-364.	0.8	47

#	ARTICLE	IF	CITATIONS
73	Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. <i>Lancet Public Health</i> , The, 2016, 1, e8-e17.	4.7	210
74	Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. <i>Lancet Public Health</i> , The, 2016, 1, e66-e75.	4.7	37
75	Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries. <i>International Journal of Cancer</i> , 2016, 139, 2771-2780.	2.3	62
76	Association of <i>GBA</i> Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 1217.	4.5	185
77	Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use. <i>BMC Health Services Research</i> , 2016, 16, 147.	0.9	36
78	Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand. <i>PLoS ONE</i> , 2016, 11, e0151619.	1.1	49
79	Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data. <i>BMC Infectious Diseases</i> , 2015, 16, 52.	1.3	19
80	Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand. <i>BMC Infectious Diseases</i> , 2015, 15, 365.	1.3	3
81	Fall in Genital Warts Diagnoses in the General and Indigenous Australian Population Following Implementation of a National Human Papillomavirus Vaccination Program: Analysis of Routinely Collected National Hospital Data. <i>Journal of Infectious Diseases</i> , 2015, 211, 91-99.	1.9	71
82	Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program. <i>BMC Infectious Diseases</i> , 2014, 14, 351.	1.3	30
83	Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. <i>Vaccine</i> , 2014, 32, 2645-2656.	1.7	23
84	Testing previous model predictions against new data on human papillomavirus vaccination program outcomes. <i>BMC Research Notes</i> , 2014, 7, 109.	0.6	14
85	Incremental Benefits of Male HPV Vaccination: Accounting for Inequality in Population Uptake. <i>PLoS ONE</i> , 2014, 9, e101048.	1.1	15
86	Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. <i>BMC Infectious Diseases</i> , 2013, 13, 114.	1.3	19
87	Cancer incidence and mortality in people aged less than 75 years: Changes in Australia over the period 1987-2007. <i>Cancer Epidemiology</i> , 2013, 37, 780-787.	0.8	20
88	Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study. <i>BMJ</i> , The, 2012, 345, e7086-e7086.	3.0	35
89	Expenditure and resource utilisation for cervical screening in Australia. <i>BMC Health Services Research</i> , 2012, 12, 446.	0.9	18
90	A revision of sexual mixing matrices in models of sexually transmitted infection. <i>Statistics in Medicine</i> , 2012, 31, 3419-3432.	0.8	9

#	ARTICLE	IF	CITATIONS
91	Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies. <i>Vaccine</i> , 2011, 29, 2487-2494.	1.7	69
92	The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. <i>Vaccine</i> , 2011, 29, 9112-9122.	1.7	58
93	Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. <i>BMC Cancer</i> , 2011, 11, 239.	1.1	51
94	Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. <i>BMC Public Health</i> , 2010, 10, 734.	1.2	35
95	The predicted impact of vaccination on human papillomavirus infections in Australia. <i>International Journal of Cancer</i> , 2008, 123, 1854-1863.	2.3	48
96	Cancer burden and control in Australia: lessons learnt and challenges remaining. <i>Annals of Cancer Epidemiology</i> , 0, 2, 3-3.	1.8	6
97	HPV screening for cervical cancer is reaching maturity. <i>BMJ</i> , The, 0, , o1303.	3.0	3